Browse Case Studies by
Case Studies in
- Corporate Governance
- Corporate Social Responsibility
- Economics
- Entrepreneurship
- Finance, Accounting & Control
- Leadership
- Marketing
- Organisational Behaviour / HRM
- Social Entrepreneurship
- Strategy
- All Case Studies »
Concept wise Case Studies
- Mergers, Acquisitions and Alliances - Vol. I
- Mergers, Acquisitions and Alliances - Vol. II
- Mergers, Acquisitions and Alliances - Vol. III
- Mergers, Acquisitions and Alliances - Vol. IV
- Airline Industry
- » All Concept wise Cases
Industry wise Case Studies
- Banking and Financing Services
- Retailing
- Energy and Utilities
- Oil and Gas Refining, Marketing and Distribution
- Commercial Aircraft Manufacturing
- » All Industry wise Cases
Region wise Case Studies
Mergers, Acquisitions, Alliances and Synergies Case Study
Case Title:
Pfizer : Mergers and Acquisitions
Publication Year : 2003
Authors: G Srikanth
Industry: Pharmaceuticals
Region: USA
Case Code: MAA0002
Teaching Note: Not Available
Structured Assignment: Not Available
OR
Abstract:
In the 1990s, the global pharmaceutical industry saw a spurt of mergers and acquisitions. Companies across the world were merging to achieve critical mass and economies of scale in all departments but more specifically in research and development. Pfizer, which had always adopted a strategy of 'organic' growth, suddenly changed its policy and turned towards 'inorganic' growth. It acquired Warner Lambert and Pharmacia to become the biggest pharmaceutical company in the world. The major driver for these acquisitions was the portfolio of blockbuster drugs of the two acquired companies.
Pedagogical Objectives:
- To discuss why Pfizer changed its trajectory from organic to inorganic growth
- To discuss the key elements in Pfizer’s acquisition of the two companies.
Keywords : Pfizer; Mergers and acquisitions; Warner Lambert; American pharmaceutical industry;Mergers, Acquisitions, Alliances Case Study ; Patented drugs; Lipitor; Pharmacia; Value chain; Celebrex; Research and development; Economies of scale; Food and Drug Administration; Co-promotions; Generic competition; Inorganic growth
